id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-D-0223-0004,FDA,FDA-2002-D-0223,An Acceptable Circular of Information for the Use of Human Blood and Blood Components; Guidance for Industry,Other,Guidance,2022-03-23T04:00:00Z,2022,3,2022-03-23T04:00:00Z,,2025-08-29T09:00:27Z,,1,0,0900006484fdb944
FDA-2002-D-0223-0003,FDA,FDA-2002-D-0223,An Acceptable Circular of Information for the Use of Human Blood and Blood Components - Level 2 Guidance,Other,GDL-Guidance (Supporting and Related Materials),2009-12-23T05:00:00Z,2009,12,2009-12-23T05:00:00Z,,2024-11-07T22:12:43Z,,1,0,0900006480a700ff
FDA-2002-D-0223-0002,FDA,FDA-2002-D-0223,Guideline,Supporting & Related Material,GDL-Guidance,2003-12-12T05:00:00Z,2003,12,,,2008-04-12T01:17:31Z,,0,0,09000064804971f1
FDA-2002-D-0223-0001,FDA,FDA-2002-D-0223,Guidance for Industry: An Acceptable Circular of Information for the Use of Human Blood and Blood Components - Draft Guidance,Notice,NAD-Notice of Availability of Data,2002-10-21T04:00:00Z,2002,10,2002-10-21T04:00:00Z,2002-12-18T04:59:59Z,2009-12-23T14:56:40Z,,0,0,09000064804971b6